Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: May 2, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Ovarian Cancer

Phase III Farletuzumab Trial Fails to Meet Endpoints in Platinum-Sensitive Disease 


A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.

The MORAb-003-004 clinical trial, also known as FAR-131, was a randomized, double-blind, placebo-controlled, global study of the safety and efficacy of weekly farletuzumab in combination with a platinum standard chemotherapy regimen (carboplatin plus a taxane) in platinum-sensitive ovarian cancer patients in first relapse.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.